iECURE
Pre-clinicalKnocking down devastation. Inserting hope. At iECURE, we believe in vivo gene editing is the answer to meeting this immense patient need, and we believe reversing the course of these conditions is now within reach.
Founded
2021
Focus
Gene TherapyRare Disease
About
Knocking down devastation. Inserting hope. At iECURE, we believe in vivo gene editing is the answer to meeting this immense patient need, and we believe reversing the course of these conditions is now within reach.
Funding History
2Total raised: $115M
Series B$65MNovo HoldingsJan 15, 2023
Series A$50MVersant VenturesAug 15, 2021
Company Info
TypePrivate
Founded2021
LocationPhiladelphia, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile